Abbott Laboratories (ABT): I Am Very Upset With Abbott,” Says Jim Cramer

We recently published Jim Cramer Discusses These 10 Stocks & AI-Led Disinflation. Abbott Laboratories (NYSE:ABT) is one of the stocks Jim Cramer recently discussed.

Abbott Laboratories (NYSE:ABT) is a healthcare company. While it was one of Cramer’s top stocks for most of this year, this show saw the CNBC TV host take a different tone. Abbott Laboratories (NYSE:ABT)’s shares fell by 8.5% in July after the firm’s latest earnings results saw it warn about a massive $1 billion hit in 2025 from tariffs. Here’s what Cramer said about the firm:

“I am very upset with Abbott. They’re on tonight. I have supported the company for years and years. It’s the diagnostic business. We’ll have Robert Ford on tonight, it’s not catastrophic because I like the company, long term. But, this is not, this was another thing that happened this morning that I found quite disturbing.

“[On low guidance] Diagnostic, China, uh yeah, so we can talk about that they have even more COVID testing issues, you don’t miss if you’re Abbott Labs.”

An operating room with a doctor monitoring a patient’s vital signs during surgery with a medical device.

Previously, Cramer discussed Abbott Laboratories (NYSE:ABT)’s earnings before the release:

“Then one of my absolute favorite companies, medical device maker, Abbott Labs reports. And you know, I always like to tell you which companies tend to be misinterpreted in a negative way during the earnings season. Abbott’s a textbook example. It bothers me, but there are always sellers who claim to be disappointed. So, if you don’t own any Abbott, may I suggest that you wait to see the numbers, wait for the stock’s opening, wait for the sellers to appear. Patience is a virtue with ABT.”

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.